Treatment of Lupus Nephritis
- First Online:
- 290 Downloads
The treatment of lupus nephritis has evolved over the past few decades. Standard practice is to define the first 6 months of therapy as an induction phase, during which the goal of therapy is to achieve renal remission, usually with bolus intravenous infusions of the cytotoxic cyclophosphamide or the immunosuppressant mycophenolate mofetil (MMF). Following induction, therapy is continued, with some decrease in aggressive dosing for a more prolonged period of time—typically 24 months—that is aimed at preventing renal flares and smoldering disease, which could lead to continuous deterioration of renal function. During maintenance, the usual therapeutic option is immunosuppression with MMF or azathioprine. In recent years, MMF has been increasingly replacing intravenous cyclophosphamide as an initial standard of care. The current paper reviews data on these treatment strategies and suggests a possible treatment algorithm for clinical care.
KeywordsLupus nephritis Systemic lupus erythematosus Cyclophosphamide Mycophenolate mofetil Treatment
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 18.• Appel GB, Contreras, G, Doolery MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12. This publication describes results of the international, randomized controlled clinical trial comparing MMF with IV CYC (ALMS trial). Patients responded similarly in both groups, and MMF was not shown to be superior to IV CYC as an induction treatment. It was also shown that the rates of adverse events, serious adverse events, and infections were not significantly different between the two groups. PubMedCrossRefGoogle Scholar
- 22.Furie R, Looney RJ, Rovin B, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study [abstract]. Arthritis Rheum. 2009;60 Suppl 10:1149.Google Scholar
- 24.Efficacy and safety study of abatacept to treat lupus nephritis. Available at http://www.clinicaltrials.gov/ct2/show/NCT00430677. Accessed November 2010.
- 25.Abatacept and cyclophosphamide combination therapy for lupus nephritis. Available at http://clinicaltrials.gov/ct2/show/NCT00774852. Accessed November 2010.
- 26.Doria A. Treatment of lupus nephritis with enteric-coated mycophenolate sodium (EC-MPS)—MyLupus exploratory study [abstract]. Arthritis Rheum. 2010;62(10):S583.Google Scholar
- 27.• Ginzler EM, Appel GB, Dooley MA, et al. Aspreva Lupus Management Study (ALMS): maintenance results [abstract]. Arthritis Rheum. 2010;62(10):S871–2. As a continuation of the ALMS induction trial, MMF was compared with AZA as a maintenance regimen for LN patients who achieved response during the induction phase. MMF was found to be superior to AZA in maintaining renal remission. Google Scholar
- 28.• Houssiau, FA, D’Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis. 2010;69:2083–9. This study presented data comparing MMF with AZA after the ELNT induction regimen. The MMF group had fewer renal flares compared with the AZA group, but this difference was not statistically significant. PubMedCrossRefGoogle Scholar